Johannes Gutenberg-Universität Mainz

Universitätsmedizin Der Johannes Gutenberg-Universitat Mainz

Johannes Gutenberg-Universitatis

Jan-Peter Kramb

Gerd Dannhardt

Stanislav Plutizki

Markus Möhler

Annett Müller

Thomas Fischer

Christian Peifer

Annett Mueller

Florian Heidel

Markus Moehler

The present invention relates to the use of a compound of formula (I) wherein Rand Rare as defined in the description and Ris a phenyl group which is substituted with 2 or 3 C-Calkoxy groups, or a physiologically acceptable salt thereof, or a solvate of the compound of formula (I) or of the salt thereof, for treatment of colorectal or gastric adenocarcinoma. 

3-(indolyl)- or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma

The present invention relates to a compound of formula (I) wherein R, Rand Rare as defined in the description and the physiologically acceptable salts thereof as well as the physiologically acceptable solvates of the compounds of formula I and of the salts thereof. The compounds of formula I are suitable for treating tumors. 

3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment

The present invention relates to a compound of formula (I) wherein Ris H, C-C-alkyl, phenyl-C-C-alkyl or phenyl, Ris a phenyl group which is substituted with 2 or 3 C-C-alkoxy groups and Ris indolyl or azaindolyl which may carry one or two substituents independently selected from C-C-alkyl, C-C-alkoxy, phenyl, OH, halogen, NH, C-C-alkylamino, di-C-C-alkylamino, heteroaryl with 5 or 6 ring atoms containing 1 or 2 heteroatoms which are independently selected from O, N, and S and heterocyclyl with 5 or 6 ring atoms containing 1 or 2 heteroatoms which are independently selected from O, N, and S and the physiologically acceptable salts thereof as well as the physiologically acceptable solvates of the compounds of formula 1 and of the salts thereof. The compounds of formula (I) are suitable for controlling angiogenesis. 

3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors

Growing community of inventors

Mainz, Germany

Jan-Peter Kramb